Karen McGlynn's Contact Details

Karen McGlynn's Company Details

BDD

84 Castle Street, ENG, UK • 54 Employees
Major Drugs

BDD combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.